Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.08.006
Taha Ahmed , Gabriel Najarro , Jingwen Huang , Kristen Harris , Viola Vaccarino , Arshed Quyyumi , Vincent L. Sorrell , Puja K. Mehta
{"title":"Trends in multimodality cardiac imaging utilization for Takotsubo syndrome hospital admissions in the United States (2017–2023)","authors":"Taha Ahmed , Gabriel Najarro , Jingwen Huang , Kristen Harris , Viola Vaccarino , Arshed Quyyumi , Vincent L. Sorrell , Puja K. Mehta","doi":"10.1016/j.pcad.2025.08.006","DOIUrl":"10.1016/j.pcad.2025.08.006","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 3-5"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.08.007
Nzechukwu M. Isiozor , Setor K. Kunutsor , Sudhir Kurl , Kai Savonen , Jussi Kauhanen , Jari A. Laukkanen
Background
Emerging evidence suggests that the Fit-Fat Index (FFI), which combines measures of fitness and fatness, may offer a more accurate assessment of cardiometabolic risk than either component alone. We aimed to investigate the prospective associations of cardiorespiratory fitness (CRF), fatness indices, and FFI variants with the risk of sudden cardiac death (SCD), and to evaluate their utility in SCD risk prediction.
Methods
Baseline assessments of CRF (measured using a respiratory gas exchange analyzer during exercise testing) and fatness indices (body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR)) were conducted in 1662 men aged 42–61 years. FFI variants (FFIBMI, FFIWHR, and FFIWHtR) were calculated by dividing CRF by each corresponding fatness measure. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were estimated using Cox regression, and improvements in risk prediction were assessed using measures of discrimination and reclassification.
Results
Over a median follow-up of 28.3 years, 172 SCDs occurred. After adjustment for confounders and potential mediators, each 1 SD increase in CRF and FFI variants was associated with a significantly lower risk of SCD: HRs (95 % CI) were 0.68 (0.56–0.82) for CRF, 0.65 (0.53–0.79) for FFIBMI, 0.66 (0.54–0.81) for FFIWHR, and 0.65 (0.53–0.80) for FFIWHtR. BMI and WHtR, but not WHR, remained associated with SCD after full adjustment. CRF and all FFI variants significantly improved model fit, net reclassification, and discrimination (p < .001 for all).
Conclusions
Higher levels of CRF and FFI variants were robustly associated with lower SCD risk and offered comparable improvements in prediction. These findings support their potential utility in clinical and research settings for SCD risk stratification.
{"title":"Fit-Fat Index and the risk of sudden cardiac death in Finnish men","authors":"Nzechukwu M. Isiozor , Setor K. Kunutsor , Sudhir Kurl , Kai Savonen , Jussi Kauhanen , Jari A. Laukkanen","doi":"10.1016/j.pcad.2025.08.007","DOIUrl":"10.1016/j.pcad.2025.08.007","url":null,"abstract":"<div><h3>Background</h3><div>Emerging evidence suggests that the Fit-Fat Index (FFI), which combines measures of fitness and fatness, may offer a more accurate assessment of cardiometabolic risk than either component alone. We aimed to investigate the prospective associations of cardiorespiratory fitness (CRF), fatness indices, and FFI variants with the risk of sudden cardiac death (SCD), and to evaluate their utility in SCD risk prediction.</div></div><div><h3>Methods</h3><div>Baseline assessments of CRF (measured using a respiratory gas exchange analyzer during exercise testing) and fatness indices (body mass index (BMI), waist-to-hip ratio (WHR), and waist-to-height ratio (WHtR)) were conducted in 1662 men aged 42–61 years. FFI variants (FFI<sub>BMI</sub>, FFI<sub>WHR</sub>, and FFI<sub>WHtR</sub>) were calculated by dividing CRF by each corresponding fatness measure. Hazard ratios (HRs) with 95 % confidence intervals (CIs) were estimated using Cox regression, and improvements in risk prediction were assessed using measures of discrimination and reclassification.</div></div><div><h3>Results</h3><div>Over a median follow-up of 28.3 years, 172 SCDs occurred. After adjustment for confounders and potential mediators, each 1 SD increase in CRF and FFI variants was associated with a significantly lower risk of SCD: HRs (95 % CI) were 0.68 (0.56–0.82) for CRF, 0.65 (0.53–0.79) for FFI<sub>BMI</sub>, 0.66 (0.54–0.81) for FFI<sub>WHR</sub>, and 0.65 (0.53–0.80) for FFI<sub>WHtR</sub>. BMI and WHtR, but not WHR, remained associated with SCD after full adjustment. CRF and all FFI variants significantly improved model fit, net reclassification, and discrimination (<em>p</em> < .001 for all).</div></div><div><h3>Conclusions</h3><div>Higher levels of CRF and FFI variants were robustly associated with lower SCD risk and offered comparable improvements in prediction. These findings support their potential utility in clinical and research settings for SCD risk stratification.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 182-189"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.05.006
Richard Kazibwe , Jeshuah Jehopio , Christopher L. Schaich , Rishi Rikhi , Saeid Mirzai , Parag A. Chevli , Juliana H. Namutebi , Sneha Chebrolu , Shannon O'Connor , Joseph Yeboah , Michael D. Shapiro
Background
Atherogenic dyslipidemia (AD), characterized by low high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG), is associated with increased cardiovascular disease (CVD) risk. This study evaluates the association between AD and CVD in hypertension treated to systolic blood pressure (SBP) targets of <120 mmHg (intensive) or < 140 mmHg (standard).
Methods
We included 9361 participants from the Systolic Blood Pressure Intervention Trial (SPRINT). Based on baseline lipid profiles, low HDL-C was defined as <40 mg/dL in men or < 50 mg/dL in women, and high TG as ≥150 mg/dL. Participants were classified into four lipid categories according to these cutoffs. AD was defined as the combination of low HDL-C and high TG. We used multivariable Cox regression to evaluate the association between lipid categories and the primary SPRINT outcome, a composite of major CVD events.
Results
Over a median 3.8-year follow-up, 726 primary outcome events occurred. The incidence of the primary outcome was 9.5% (n = 104) in those with AD and 7.4% (n = 434) with normal HDL-C and TG. Compared to the reference group (normal HDL-C with normal TG), the hazard ratios (HRs) for primary outcome were 1.07 (95 % CI: 0.85–1.35) for high TG alone, 1.20 (95 % CI: 0.95–1.52) for low HDL-C alone, and 1.41 (95 % CI: 1.12–1.77) for AD. Similarly, HRs for the primary outcome associated with AD were 1.38 (95 % CI: 1.02–1.87) and 1.44 (95 % CI: 1.01–2.05) in the standard and intensive SBP-lowering arms, respectively.
Conclusion
Among SPRINT participants, AD was associated with a higher CVD risk. Early detection of AD in hypertensive patients, even without diabetes, may prompt greater therapeutic effort to reduce long-term CVD risk.
{"title":"Atherogenic dyslipidemia and incident cardiovascular events in high-risk hypertension","authors":"Richard Kazibwe , Jeshuah Jehopio , Christopher L. Schaich , Rishi Rikhi , Saeid Mirzai , Parag A. Chevli , Juliana H. Namutebi , Sneha Chebrolu , Shannon O'Connor , Joseph Yeboah , Michael D. Shapiro","doi":"10.1016/j.pcad.2025.05.006","DOIUrl":"10.1016/j.pcad.2025.05.006","url":null,"abstract":"<div><h3>Background</h3><div>Atherogenic dyslipidemia (AD), characterized by low high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides (TG), is associated with increased cardiovascular disease (CVD) risk. This study evaluates the association between AD and CVD in hypertension treated to systolic blood pressure (SBP) targets of <120 mmHg (intensive) or < 140 mmHg (standard).</div></div><div><h3>Methods</h3><div>We included 9361 participants from the Systolic Blood Pressure Intervention Trial (SPRINT). Based on baseline lipid profiles, low HDL-C was defined as <40 mg/dL in men or < 50 mg/dL in women, and high TG as ≥150 mg/dL. Participants were classified into four lipid categories according to these cutoffs. AD was defined as the combination of low HDL-C and high TG. We used multivariable Cox regression to evaluate the association between lipid categories and the primary SPRINT outcome, a composite of major CVD events.</div></div><div><h3>Results</h3><div>Over a median 3.8-year follow-up, 726 primary outcome events occurred. The incidence of the primary outcome was 9.5% (n = 104) in those with AD and 7.4% (n = 434) with normal HDL-C and TG. Compared to the reference group (normal HDL-C with normal TG), the hazard ratios (HRs) for primary outcome were 1.07 (95 % CI: 0.85–1.35) for high TG alone, 1.20 (95 % CI: 0.95–1.52) for low HDL-C alone, and 1.41 (95 % CI: 1.12–1.77) for AD. Similarly, HRs for the primary outcome associated with AD were 1.38 (95 % CI: 1.02–1.87) and 1.44 (95 % CI: 1.01–2.05) in the standard and intensive SBP-lowering arms, respectively.</div></div><div><h3>Conclusion</h3><div>Among SPRINT participants, AD was associated with a higher CVD risk. Early detection of AD in hypertensive patients, even without diabetes, may prompt greater therapeutic effort to reduce long-term CVD risk.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 121-127"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144113154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.08.008
Roberto Bolli , Joshua M. Hare , Emerson C. Perin , Arshed Quyyumi , Javed Butler , Dinesh K. Kalra
The prevalence of heart failure (HF) in developed countries has reached epidemic proportions and continues to rise. Despite therapeutic advances, HF remains associated with significant morbidity and mortality and thus constitutes a major public health problem that necessitates new treatment options. Cell therapy is a potential new approach to improve outcomes in HF that was first introduced two decades ago and has evolved significantly since then. Although the mechanism of action remains unclear and pivotal, large-scale trials have not been performed, numerous studies have demonstrated the safety of using various cell products in patients with HF, and several randomized, double-blind, Phase II or III trials have shown beneficial effects of cell therapy, particularly with mesenchymal stromal cells (MSCs), on clinical outcomes in ischemic and nonischemic cardiomyopathy, after administration of a single dose of cells. These potential efficacy signals, coupled with the robust record of safety, provide a solid rationale for pursuing further studies that will conclusively evaluate efficacy. New cell types, such as induced pluripotent cell-derived myocytes, and new strategies, such as repeated doses and intravenous delivery, are being tested in ongoing trials. In contrast, embryonic stem cells are unlikely to become a clinical therapy. Rigorous, well-designed, large clinical trials have the potential to pave the way for cell therapy to become a useful treatment option for patients with HF. This review summarizes the conceptual and clinical progress made in our understanding of cell therapy for HF, particularly over the past decade, and explores future horizons for the application of this treatment in HF.
{"title":"Cell therapy for heart failure -recent progress and future directions","authors":"Roberto Bolli , Joshua M. Hare , Emerson C. Perin , Arshed Quyyumi , Javed Butler , Dinesh K. Kalra","doi":"10.1016/j.pcad.2025.08.008","DOIUrl":"10.1016/j.pcad.2025.08.008","url":null,"abstract":"<div><div>The prevalence of heart failure (HF) in developed countries has reached epidemic proportions and continues to rise. Despite therapeutic advances, HF remains associated with significant morbidity and mortality and thus constitutes a major public health problem that necessitates new treatment options. Cell therapy is a potential new approach to improve outcomes in HF that was first introduced two decades ago and has evolved significantly since then. Although the mechanism of action remains unclear and pivotal, large-scale trials have not been performed, numerous studies have demonstrated the safety of using various cell products in patients with HF, and several randomized, double-blind, Phase II or III trials have shown beneficial effects of cell therapy, particularly with mesenchymal stromal cells (MSCs), on clinical outcomes in ischemic and nonischemic cardiomyopathy, after administration of a single dose of cells. These potential efficacy signals, coupled with the robust record of safety, provide a solid rationale for pursuing further studies that will conclusively evaluate efficacy. New cell types, such as induced pluripotent cell-derived myocytes, and new strategies, such as repeated doses and intravenous delivery, are being tested in ongoing trials. In contrast, embryonic stem cells are unlikely to become a clinical therapy. Rigorous, well-designed, large clinical trials have the potential to pave the way for cell therapy to become a useful treatment option for patients with HF. This review summarizes the conceptual and clinical progress made in our understanding of cell therapy for HF, particularly over the past decade, and explores future horizons for the application of this treatment in HF.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 66-79"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144984337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.09.003
Kamil Stankowski , Benedetta Volpi , Francesco Balata , Lodovico Buonamici , Matteo Biroli , Stefano Figliozzi , Anna Maltagliati , Elisabetta Mancini , Valentina Mantegazza , Mauro Pepi , Manuela Muratori , Federico De Marco , Fabio Fazzari , Francesco Cannata , Gianluca Pontone
Left atrial appendage (LAA) closure has emerged as a critical therapeutic option for stroke prevention in patients with atrial fibrillation who are unsuitable for long-term oral anticoagulation. Multimodality imaging plays a pivotal role throughout the LAA closure process, from pre-procedural planning to long-term follow-up. This review focuses on the complementary roles of cardiac computed tomography (CCT) and transesophageal echocardiography (TEE), outlining their respective strengths and limitations in various phases of LAA management, while also discussing the roles of intracardiac echocardiography (ICE) and fluoroscopy. Pre-procedurally, CCT and TEE provide detailed anatomical characterization of the LAA, including morphology, ostial dimensions, and adjacent structures, aiding device sizing and selection. TEE, with its real-time imaging capabilities, remains essential intra-procedurally for guiding device deployment, assessing sealing, and identifying complications such as pericardial effusion or device embolization. The role of ICE as a lesser invasive intraprocedural alternative is steadily growing. Post-procedural and long-term follow-up imaging relies on both modalities to evaluate for residual leaks, device-related thrombus, embolization and other potential complications. The integration of CCT and TEE enhances procedural safety, accuracy, and long-term efficacy. This review underscores the importance of a tailored, patient-specific approach to imaging, leveraging the synergistic advantages of CCT and TEE to optimize outcomes in LAA closure.
{"title":"Multimodality imaging assessment of the left atrial appendage for percutaneous closure","authors":"Kamil Stankowski , Benedetta Volpi , Francesco Balata , Lodovico Buonamici , Matteo Biroli , Stefano Figliozzi , Anna Maltagliati , Elisabetta Mancini , Valentina Mantegazza , Mauro Pepi , Manuela Muratori , Federico De Marco , Fabio Fazzari , Francesco Cannata , Gianluca Pontone","doi":"10.1016/j.pcad.2025.09.003","DOIUrl":"10.1016/j.pcad.2025.09.003","url":null,"abstract":"<div><div>Left atrial appendage (LAA) closure has emerged as a critical therapeutic option for stroke prevention in patients with atrial fibrillation who are unsuitable for long-term oral anticoagulation. Multimodality imaging plays a pivotal role throughout the LAA closure process, from pre-procedural planning to long-term follow-up. This review focuses on the complementary roles of cardiac computed tomography (CCT) and transesophageal echocardiography (TEE), outlining their respective strengths and limitations in various phases of LAA management, while also discussing the roles of intracardiac echocardiography (ICE) and fluoroscopy. Pre-procedurally, CCT and TEE provide detailed anatomical characterization of the LAA, including morphology, ostial dimensions, and adjacent structures, aiding device sizing and selection. TEE, with its real-time imaging capabilities, remains essential intra-procedurally for guiding device deployment, assessing sealing, and identifying complications such as pericardial effusion or device embolization. The role of ICE as a lesser invasive intraprocedural alternative is steadily growing. Post-procedural and long-term follow-up imaging relies on both modalities to evaluate for residual leaks, device-related thrombus, embolization and other potential complications. The integration of CCT and TEE enhances procedural safety, accuracy, and long-term efficacy. This review underscores the importance of a tailored, patient-specific approach to imaging, leveraging the synergistic advantages of CCT and TEE to optimize outcomes in LAA closure.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 80-96"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-01DOI: 10.1016/j.pcad.2025.08.010
Vikash Jaiswal MD , Muhammad Hanif MD , Danisha Kumar MBBS , Yusra Mashkoor MBBS , Vamsi Garimella MD , Sahas Reddy Jitta MD , Tushar Kumar MD , Raheel Ahmed MD , Jishanth Mattumpuram MD , Arman Qamar MD , Gregg C. Fonarow MD , Carl J. Lavie MD
Background
Colchicine, an anti-inflammatory agent, has been demonstrated to reduce adverse cardiovascular events in coronary artery disease (CAD) patients. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) provide cardiovascular prevention beyond glycemic control including anti-inflammatory effect, and reduced heart failure risk. Given their complementary mechanisms, combining colchicine and SGLT2i may offer synergistic benefits in CAD patients with T2DM, yet the incremental effects of this combination remain underexplored.
Objective
This study aimed to assess the comparative effectiveness of combination therapy of SGLT2i with colchicine vs colchicine alone among patients with CAD and T2DM.
Methods
The TriNeTX Global Collaborative Network research database was used to identify patients aged ≥18 years of age from January 2015 to June 2024. Patients were categorized into two groups: one with a combination therapy of colchicine and SGLT2i and a control group with colchicine alone. Individuals were matched based on CVD risk factors and medications. After propensity score matching, Risk ratios (RR) were used to compare outcomes over follow-up periods of 6 months and 1 year.
Results
After 1:1 propensity score matching, the study cohort comprised 12,235 patients on colchicine and SGLT2i and 12,235 patients in the control group. The study population had a mean age of 71.5 ± 16.7 years. PSM analysis showed that combination therapy of colchicine and SGLT2i in CAD patients was associated with significantly lower risk of major adverse CVD events (MACE) after 6 month (RR, 0.70 (95 %CI 0.61–0.80), p < 0.01), after 1 year (RR, 0.78 (95 %CI 0.70–0.87), p < 0.01), all-cause mortality (ACM) after 6 month (RR, 0.50 (95 %CI 0.43–0.57), P < 0.01), after 1 year (RR, 0.57 (95 %CI 0.51–0.63), p < 0.01), heart failure excacerbation (HFE) after 6 month (RR, 0.80 (95 % CI 0.69–0.93), p < 0.01), after 1 year (RR, 0.81 (95 % CI 0.72–0.92), p < 0.01), and atrial fibrillation (AF) after 6 month (RR, 0.76 (95 %CI 0.63–0.91), p < 0.01) when compared with colchicine alone. However, the risks of ischemic stroke, acute myocardial infarction (AMI) and hemorrhagic stroke were comparable between the colchicine and SGLT2i groups and the colchicine alone group.
Conclusion
This study suggests that SGLT2i use along with colchicine was associated with significantly lower risk of mortality, MACE, and HFE among CAD patients in comparison to colchicine alone.
{"title":"Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors along with colchicine versus colchicine alone among coronary artery disease and type 2 diabetes patients","authors":"Vikash Jaiswal MD , Muhammad Hanif MD , Danisha Kumar MBBS , Yusra Mashkoor MBBS , Vamsi Garimella MD , Sahas Reddy Jitta MD , Tushar Kumar MD , Raheel Ahmed MD , Jishanth Mattumpuram MD , Arman Qamar MD , Gregg C. Fonarow MD , Carl J. Lavie MD","doi":"10.1016/j.pcad.2025.08.010","DOIUrl":"10.1016/j.pcad.2025.08.010","url":null,"abstract":"<div><h3>Background</h3><div>Colchicine, an anti-inflammatory agent, has been demonstrated to reduce adverse cardiovascular events in coronary artery disease (CAD) patients. Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) provide cardiovascular prevention beyond glycemic control including anti-inflammatory effect, and reduced heart failure risk. Given their complementary mechanisms, combining colchicine and SGLT2i may offer synergistic benefits in CAD patients with T2DM, yet the incremental effects of this combination remain underexplored.</div></div><div><h3>Objective</h3><div>This study aimed to assess the comparative effectiveness of combination therapy of SGLT2i with colchicine vs colchicine alone among patients with CAD and T2DM.</div></div><div><h3>Methods</h3><div>The TriNeTX Global Collaborative Network research database was used to identify patients aged ≥18 years of age from January 2015 to June 2024. Patients were categorized into two groups: one with a combination therapy of colchicine and SGLT2i and a control group with colchicine alone. Individuals were matched based on CVD risk factors and medications. After propensity score matching, Risk ratios (RR) were used to compare outcomes over follow-up periods of 6 months and 1 year.</div></div><div><h3>Results</h3><div>After 1:1 propensity score matching, the study cohort comprised 12,235 patients on colchicine and SGLT2i and 12,235 patients in the control group. The study population had a mean age of 71.5 ± 16.7 years. PSM analysis showed that combination therapy of colchicine and SGLT2i in CAD patients was associated with significantly lower risk of major adverse CVD events (MACE) after 6 month (RR, 0.70 (95 %CI 0.61–0.80), <em>p</em> < 0.01), after 1 year (RR, 0.78 (95 %CI 0.70–0.87), <em>p</em> < 0.01), all-cause mortality (ACM) after 6 month (RR, 0.50 (95 %CI 0.43–0.57), <em>P</em> < 0.01), after 1 year (RR, 0.57 (95 %CI 0.51–0.63), <em>p</em> < 0.01), heart failure excacerbation (HFE) after 6 month (RR, 0.80 (95 % CI 0.69–0.93), p < 0.01), after 1 year (RR, 0.81 (95 % CI 0.72–0.92), p < 0.01), and atrial fibrillation (AF) after 6 month (RR, 0.76 (95 %CI 0.63–0.91), p < 0.01) when compared with colchicine alone. However, the risks of ischemic stroke, acute myocardial infarction (AMI) and hemorrhagic stroke were comparable between the colchicine and SGLT2i groups and the colchicine alone group.</div></div><div><h3>Conclusion</h3><div>This study suggests that SGLT2i use along with colchicine was associated with significantly lower risk of mortality, MACE, and HFE among CAD patients in comparison to colchicine alone.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"92 ","pages":"Pages 192-200"},"PeriodicalIF":7.6,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145002349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.pcad.2025.08.001
Daniel P. Morin , Mina K. Chung
{"title":"Recent and ongoing developments in electrophysiology science and treatment","authors":"Daniel P. Morin , Mina K. Chung","doi":"10.1016/j.pcad.2025.08.001","DOIUrl":"10.1016/j.pcad.2025.08.001","url":null,"abstract":"","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 1-2"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144860032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.pcad.2025.06.001
Peter G. Pantlin , Sahil Bharwani , Mina K. Chung , Daniel P. Morin
Class 1C antiarrhythmic drugs (AADs) are a key treatment option for effective rhythm control in several common arrhythmias. Here, we review the relevant background on Class 1C AADs, these drugs' indications and contraindications, and potential safe ways to use them. The safety profile of 1C AADs, and related restrictions on their use, has been largely based on the decades-old CAST trial, but more recent evidence may favor re-evaluating previously excluded populations. This review examines opportunities to reconsider certain patient populations that have previously been excluded from the use of 1C AADs. This reconsideration is made feasible due to advances in cardiac reperfusion, medical therapies for heart failure, and cardiac imaging.
{"title":"Is it safe to use class 1C antiarrhythmic drugs in patients with coronary artery disease and/or cardiomyopathy?","authors":"Peter G. Pantlin , Sahil Bharwani , Mina K. Chung , Daniel P. Morin","doi":"10.1016/j.pcad.2025.06.001","DOIUrl":"10.1016/j.pcad.2025.06.001","url":null,"abstract":"<div><div>Class 1C antiarrhythmic drugs<span> (AADs) are a key treatment option for effective rhythm control in several common arrhythmias. Here, we review the relevant background on Class 1C AADs, these drugs' indications and contraindications, and potential safe ways to use them. The safety profile of 1C AADs, and related restrictions on their use, has been largely based on the decades-old CAST trial, but more recent evidence may favor re-evaluating previously excluded populations. This review examines opportunities to reconsider certain patient populations that have previously been excluded from the use of 1C AADs. This reconsideration is made feasible due to advances in cardiac reperfusion, medical therapies for heart failure, and cardiac imaging.</span></div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 28-32"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144277101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.pcad.2025.06.008
Samuel Harwood , M. Benjamin Shoemaker , John Barnard , David R. Van Wagoner , Daniel P. Morin , Mina K. Chung
With the demonstration that AF is highly hereditable and strongly associated with over 100 genetic loci, one step towards personalized treatment of AF is the potential use of genetic testing to predict response to therapy. Although various clinical models have been developed to predict recurrence, none have shown a consistent ability to predict treatment outcomes. This highlights a need for additional patient information to increase predictive value. Here, we review the use of genetic data for prediction of AF recurrence after interventions such as ablation, cardioversion, or drug therapy. We explore the use of other downstream predictors, such as mRNA and protein, as other possible predictive tools. Finally, we assess how this genetic data can further our mechanistc understanding of AF pathogenesis and recurrence.
{"title":"Genomics in atrial fibrillation: Predicting recurrence of AF after treatment using genetics","authors":"Samuel Harwood , M. Benjamin Shoemaker , John Barnard , David R. Van Wagoner , Daniel P. Morin , Mina K. Chung","doi":"10.1016/j.pcad.2025.06.008","DOIUrl":"10.1016/j.pcad.2025.06.008","url":null,"abstract":"<div><div>With the demonstration that AF is highly hereditable and strongly associated with over 100 genetic loci, one step towards personalized treatment of AF is the potential use of genetic testing to predict response to therapy. Although various clinical models have been developed to predict recurrence, none have shown a consistent ability to predict treatment outcomes. This highlights a need for additional patient information to increase predictive value. Here, we review the use of genetic data for prediction of AF recurrence after interventions such as ablation, cardioversion, or drug therapy. We explore the use of other downstream predictors, such as mRNA and protein, as other possible predictive tools. Finally, we assess how this genetic data can further our mechanistc understanding of AF pathogenesis and recurrence.</div></div>","PeriodicalId":21156,"journal":{"name":"Progress in cardiovascular diseases","volume":"91 ","pages":"Pages 62-66"},"PeriodicalIF":7.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144512963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号